{"id":11,"date":"2018-04-01T20:08:14","date_gmt":"2018-04-01T19:08:14","guid":{"rendered":"https:\/\/admin.innaxon.cz\/?page_id=11"},"modified":"2020-06-24T09:42:48","modified_gmt":"2020-06-24T08:42:48","slug":"iaxo-small-molecules","status":"publish","type":"page","link":"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/","title":{"rendered":"Technology"},"content":{"rendered":"<h2><strong>About IAXO compounds<\/strong><\/h2>\n<p>IAXO compounds are Glycolipids and Benzylammonium Lipids\u00a0designed to act as Lipid A analogues that\u00a0hold considerable promise in pharmacological settings, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4\u2019s key role in the defence of pathogens. CD14-dependent and independent TLR4 activation of immune and non-immune cells by endogenous factors have been recently shown in a proof of concept preclinical study for inflammatory diseases such as an abdominal aortic aneurysm (AAA).<\/p>\n<p>Persistent inflammation has been implicated in the pathogenesis not only of diverse chronic diseases such as neuropathic pain, atherosclerosis, chronic hepatitis, and abdominal aortic aneurysm, but also acute organ failure, cardiac infarct and stroke.<\/p>\n<h2><strong><br \/>\nToll-like receptors<\/strong><\/h2>\n<p>The Toll-like receptor (TLR) family members are key contributors to these pro-inflammatory conditions. These pattern recognition receptors respond to molecular patterns in components of bacteria and viruses. In addition to their role in detecting pathogen-associated molecular patterns (PAMPs), TLRs can also sense endogenous danger (or tissue damage) associated molecular patterns (DAMPs) and have been implicated in perpetuating inflammatory cascades in the absence of invading microbes or other pathogens.<\/p>\n<p>TLR4\u2019s well-known key role in orchestrating innate and adaptive immune response to Gram-negative bacteria now extends into the area of mediating auto-inflammation and tissue repair and remodelling.<\/p>\n<p>The novel family of synthetic IAXO compounds not only can inhibit LPS-stimulated TLR4 activation by competitively occupying CD14 and thereby reducing the delivery of activating endotoxin to MD-2-TLR4 but may also shed light on the features of CD14-dependent and TLR4-independent signalling pathways triggered by TLR4 ligands other than LPS (endogenous danger molecules, such as HMGB1).<\/p>\n<p>The functional properties described so far suggest that molecules IAXO-101 and IAXO-102an be considered lead compounds in the development of new agents selectively targeting the TLR4\/CD14 mediated sterile inflammation.<\/p>\n<p>IAXO compounds are effective in rodent models of inflammatory diseases (1-10 mg\/kg) showing a good toxicity profile.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>About IAXO compounds IAXO compounds are Glycolipids and Benzylammonium Lipids\u00a0designed to act as Lipid A analogues that\u00a0hold considerable promise in pharmacological settings, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4\u2019s key role in the defence of pathogens. CD14-dependent and independent TLR4 activation of immune and non-immune cells<\/p>\n<p><a class=\"more-link\" href=\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/\">Read More<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-11","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Technology - Innaxon, s.r.o.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Technology - Innaxon, s.r.o.\" \/>\n<meta property=\"og:description\" content=\"About IAXO compounds IAXO compounds are Glycolipids and Benzylammonium Lipids\u00a0designed to act as Lipid A analogues that\u00a0hold considerable promise in pharmacological settings, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4\u2019s key role in the defence of pathogens. CD14-dependent and independent TLR4 activation of immune and non-immune cellsRead More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/\" \/>\n<meta property=\"og:site_name\" content=\"Innaxon, s.r.o.\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-24T08:42:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/\",\"url\":\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/\",\"name\":\"Technology - Innaxon, s.r.o.\",\"isPartOf\":{\"@id\":\"https:\/\/www.innaxon.cz\/#website\"},\"datePublished\":\"2018-04-01T19:08:14+00:00\",\"dateModified\":\"2020-06-24T08:42:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.innaxon.cz\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.innaxon.cz\/#website\",\"url\":\"https:\/\/www.innaxon.cz\/\",\"name\":\"Innaxon, s.r.o.\",\"description\":\"Targeting Innate Immunity For Therapeutic Benefit\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.innaxon.cz\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Technology - Innaxon, s.r.o.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/","og_locale":"en_GB","og_type":"article","og_title":"Technology - Innaxon, s.r.o.","og_description":"About IAXO compounds IAXO compounds are Glycolipids and Benzylammonium Lipids\u00a0designed to act as Lipid A analogues that\u00a0hold considerable promise in pharmacological settings, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4\u2019s key role in the defence of pathogens. CD14-dependent and independent TLR4 activation of immune and non-immune cellsRead More","og_url":"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/","og_site_name":"Innaxon, s.r.o.","article_modified_time":"2020-06-24T08:42:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/","url":"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/","name":"Technology - Innaxon, s.r.o.","isPartOf":{"@id":"https:\/\/www.innaxon.cz\/#website"},"datePublished":"2018-04-01T19:08:14+00:00","dateModified":"2020-06-24T08:42:48+00:00","breadcrumb":{"@id":"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.innaxon.cz\/index.php\/iaxo-small-molecules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.innaxon.cz\/"},{"@type":"ListItem","position":2,"name":"Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.innaxon.cz\/#website","url":"https:\/\/www.innaxon.cz\/","name":"Innaxon, s.r.o.","description":"Targeting Innate Immunity For Therapeutic Benefit","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.innaxon.cz\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages\/11","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/comments?post=11"}],"version-history":[{"count":7,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages\/11\/revisions"}],"predecessor-version":[{"id":376,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages\/11\/revisions\/376"}],"wp:attachment":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/media?parent=11"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}